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A ligand-mediated dimerization mode for vancomycin 
Patrick J LoIll, Russ Miller *13, Charles M Weeks* and Paul H Axelsenl 
Background: Vancomycin and related glycopeptide antibiotics exert their 
antimicrobial effect by binding to carboxy-terminal peptide targets in the 
bacterial cell wall and preventing the biosynthesis of peptidoglycan. Bacteria 
can resist the action of these agents by replacing the peptide targets with 
depsipeptides. Rational efforts to design new agents effective against resistant 
bacteria require a thorough understanding of the structural determinants of 
peptide recognition by vancomycin. 
Results: The crystal structure of vancomycin in complex with /V-acetyl-D-alanine 
has been determined at atomic resolution. Two different oligomeric interactions 
are seen in the structure: back-to-back dimers, as previously described for the 
vancomycin-acetate complex, and novel face-to-face dimers, mediated largely 
by the bound ligands. Models of longer, naturally occurring peptide ligands may 
be built by extension of Wacetyl-b-alanine. These larger ligands can form an 
extensive array of polar and nonpolar interactions with two vancomycin 
monomers in the face-to-face configuration. 
Conclusions: A new dimeric form of vancomycin has been found in which two 
monomers are related in a face-to-face configuration, and bound ligands 
comprise a large portion of the dimer interface. The relative importance of face- 
to-face and back-to-back dimers to the antimicrobial activity of vancomycin 
remains to be established, but face-to-face interactions appear to explain how 
increased antimicrobial activity may arise in covalent vancomycin dimers. 
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Introduction 
Glycopeptide antibiotics such as vancomycin and teico- 
planin are often used for the treatment of severe life-threat- 
ening infections when no other agents are effective or 
available. Unfortunately, high level bacterial resistance has 
significantly eroded the effectiveness of these ‘drugs of last 
resort’ over the past decade [l]. There is an urgent need for 
new antimicrobial agents in this class to overcome emerging 
resistance, and this need is propelling new investigations 
into the mode and site of action of glycopeptide antibiotics. 
An important insight into the process by which glycopep- 
tide antibiotics recognize their target ligands in bacterial 
cell walls was provided through nuclear magnetic reso- 
nance (NMR) investigations that suggested that these 
antibiotics formed dimers [Z-.5] and that dimerization could 
significantly enhance ligand affinity [6-141. It was con- 
cluded that vancomycin dimerized in a ‘back-to-back’ con- 
figuration, with segments of antiparallel p structure forming 
both at the ‘back’ of each monomer, across the dimer inter- 
face between heptapeptide backbones, and at the ‘front’ of 
each monomer, between the drug and its ligand. X-ray 
crystallography has since verified this back-to-back antipar- 
allel p configuration in balhimycin and vancomycin crystals, 
and has also shown that the aromatic rings and the sugar 
residues in these compounds engage in an extensive array 
of interactions across the dimer interface [S-17]. 
Dimerization is believed to promote antimicrobial action 
because the binding of one monomer to the bacterial cell 
wall brings a second monomer into proximity with other 
peptidoglycan ligands, leading to the formation of a 
‘chelate’ with the peptidoglycan [8,14]. Back-to-back 
dimerization also increases the affinity between ligands 
and individual monomers, however [6,12,14]. At least 
three mechanisms have been suggested to explain this 
allosteric effect. First, dimerization may induce conforma- 
tional changes, or suppress thermomolecular deforma- 
tions, and thereby yield a more favorable site for ligand 
binding 112,171. Second, dimerization may position posi- 
tively charged groups such that the negatively charged 
carboxyl terminus of a ligand is attracted into the binding 
site [12]. Third, antiparallel p structure in a dimer may 
polarize the backbone peptide groups involved in ligand 
binding and strengthen their hydrogen-bonding potential 
[17]. These mechanisms are mutually compatible, and all 
may contribute to ligand affinity. 
Recent investigations demonstrate that covalently linked 
vancomycin monomers can show markedly increased 
affinity for depsipeptide ligands and significant antimicro- 
bial activity against vancomycin-resistant bacteria [l&19]. 
These properties, and the requirement for rather long 
molecular linkages between vancomycin monomers 
(> 10 if), suggest that covalent linkage does not enhance 
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Figure 1 
Chemical structures of vancomycin and 
AcDA. The seven amino acid residues in 
vancomycin are indicated (l-7). 
activity by promoting the same types of interactions found 
in noncovalent back-to-back dimers. In this report, we 
describe the crystal structure of vancomycin in complex 
with N-acetyl-D-alanine (AcDA). This complex illustrates 
the ability of vancomycin to form ‘face-to-face’ dimers, 
and suggests that face-to-face interactions may account for 
the enhanced ligand affinity and antimicrobial efficacy of 
covalently linked monomers. 
Results and discussion 
Nomenclature 
Residues in the vancomycin-AcDA structure are referred 
to in a similar manner to those described previously by 
Loll et al. [17]. The four independent molecules of van- 
comycin are designated VI-V4, with the seven individual 
amino acid residues within each monomer designated 
Vl:l-V1:7, VZ:l-V2:7, and so on (Figure 1). The glucose 
and vancosamine residues are indicated by ‘G’ or ‘V’ in 
place of a residue number. The corresponding ligands are 
designated AcDAl-AcDA4, and there are four chloride 
ions, Cl-l-Cl-4 in each asymmetric unit. 
Structure description 
There are four copies each of vancomycin, AcDA and Cl- 
in the asymmetric unit of vancomycin-AcDA crystals, 
implying that four countercations remain unidentified. 
These molecules form two asymmetric dimers (Vl-V3 
and VZ-V4), similar to those seen in the ureido-bal- 
himycin and vancomycin-acetate structures (Figure 2). 
VI and V2, along with their ligands, are nearly identical 
and may be superimposed with a root mean square (rms) 
difference of < 0.2 A. The configuration of their disac- 
charides corresponds to that seen in the ligand-bound 
monomer of the vancomycin-acetate complex (VZ), that 
is the glucose residue overhangs the ligand-binding site. 
Likewise, V3 and V4 are nearly identical and Fay be 
superimposed with an rms difference of < 0.2 A. The 
configuration of their disaccharides, however, corre- 
sponds to that of the ligand-free monomer of the van- 
comycin-acetate complex (VI), so the vancosamine 
residue overhangs the ligand-binding site. Apart from 
opposite orientations for the disaccharides, Vl and VZ are 
quite similar to V3 and V4, and may be superimposed 
with an rms difference of < 0.4 A. 
The charged amino groups of Vl:V and V2:V hydrogen 
bond with the backbone carbonyl oxygen atoms of V2:2 
and V1:2, respectively. These relationships are analogous 
to those found across the dimer interface in the crystal 
structure of vancomycin between the charged amino 
group of vancosamine on residue 6 and the backbone car- 
bony1 of residue 2. It is noteworthy that the carbonyl 
groups of V3:2 and V4:2 are not similarly bound, but that 
electron densities assigned to water molecules 8 and 20 
may be sodium cations in analogous positions. 
Ligand binding 
The ligand in Vl and V2 of the AcDA complex is situated 
slightly higher in the binding site than in V3 and V4 
(when oriented with the disaccharide upwards). The chief 
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Figure 2 
Stereoview of the vancomycin-AcDA 
face-face dimer. Atoms of vancomycin are 
space-filling models, except for the 
disaccharide units which are bail-and-stick. 
Atoms of AcDA are represented as tubes. 
Blue, carbon; green, chlorine; red, oxygen; 
yellow, nitrogen. 
interaction causing this difference appears to be steric 
repulsion between the C, methyl of vancosamine in V3/V4 
and the alanyl methyl group of the ligand. The ligands 
adopt essentially the same configuration in all four 
binding sites, however, with backbone 9 angles in the 
range of -22.7 to -26.2” [ZO]. 
The vancomycin-AcDA complex adopts a different crystal 
form than either the acetate or N-acetyl-glycine complexes 
([17]; P.J.L., unpublished observations), which reflects the 
differences in affinity between the drug and these differ- 
ent ligands. The ratio of vancomycin:ligand is 1:l in the 
AcDA complex, whereas it is 21 in the acetate and glycine 
complexes. Molecule Vl in the acetate and glycine com- 
plexes is bound to a symmetry-related copy of itself 
(residue Vl:l) instead of to the ligand. Thus, AcDA pre- 
sumably has a higher affinity for the binding site than 
Vl:l, thereby precluding formation of the crystal form 
seen in acetate and glycine crystals. 
Dimer formation 
Vancomycin-AcDA forms back-to-back dimers as seen 
previously in the crystal structures of balhimycin [15] and 
vancomycin-acetate [16,17]. Of interest, however, is the 
observation that Vl, in addition to forming the back-to- 
back dimer with V3, also forms a face-to-face dimer with a 
symmetry-related copy of V3 (Figure 3). The same rela- 
tionships are observed between V2 and V4. The bound 
AcDA ligands comprise a significant portion of these face- 
to-face dimer interfaces. Direct contact between Vl and 
V3 is limited to hydrophobic interactions between Vl:l 
and V3:l (similarly for V2:l and V4:1), but the ligand 
bound to Vl makes more extensive contact with V3, 
including a hydrogen bond between the acetate carbonyl 
of AcDAl and the quaternary nitrogen of V3:l (similarly 
for AcDA2 and V4: 1). 
Natural ligand model 
The natural peptidoglycan target of vancomycin in bac- 
terial cell walls terminates in -D-Clu-L-Dap-D-Ala- 
D-Ala (Dap, meso-a,&-diaminopimelate). Two copies of 
Figure 3 
Schematic (above) and actual (below) views of the infinite chains of 
vancomycin monomers that comprise the crystal lattice. These chains 
are made up of alternating back-to-back and face-to-face contacts 
between monomers. Vl are blue and V3 are pink; their respective 
AcDA ligands are orange and yellow. There are two such chains of 
monomers found in this crystal form. Monomers in both chains pack in 
an essentially identical fashion, even though the chains are 
crystallographically independent. Only one chain is shown for clarity. 
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Figure 4 
Stereoview of the vancomycin face-to-face dimer with the two AcDA ligands extended to illustrate a plausible binding mode for two AC-D-GILI- 
L-Dap-D-Ala-o-Ala ligands. The position of the carboxy-terminal o-alanine residue is unchanged from the vancomycin-AcDA crystal structure. 
this natural ligand were modeled into the face-to-face favorably with those seen across the back-to-back dimer 
vancomycin-AcDA structure as extensions of the AcDA interface (Figure 5). 
ligands (Figure 4). In the model, the D-Glu-L-Dap- 
D-Ala-D-Ala ligands form a plausible and extensive inter- Significance 
face between two of the vancomycin molecules desig- Bacterial resistance to glycopeptide antibiotics such as 
nated Vl and V3. The nature and number of interactions vancomycin is emerging; a greater knowledge of the 
possible across a face-to-face dimer interface compare mode and site of action of such antibiotics is needed to 
Figure 5 
Chemistry & Biology 
Schematic view of the molecular interactions 
between one ligand and two vancomycin 
monomers in the face-to-face dimer. Thin 
dashed lines (dark blue) represent polar 
interactions; thick dashed lines (light blue) 
represent nonpolar contact, Electropositive 
groups are blue (peptide hydrogens and 
charged nitrogens); electronegative groups 
(carbonyl and carboxylate oxygens) are red. 
Note that the positively charged amino group 
of L-Dap interacts with the electronegative 
aromatic It-electron system of residue 6. 
combat this resistance. Here, the determination of the 
crystal structure of vancomycin in complex with 
N-acetyl-D-alanine (AcDA) demonstrates that van- 
comycin forms ligand-mediated face-to-face dimers as 
well as the ligand-independent back-to-back dimers pre- 
viously observed by nuclear magnetic resonance. 
The results cannot prove that face-to-face dimerization 
is important for the antimicrobial activity of van- 
comycin, but our finding that two nearly identical crys- 
tallographically independent copies of this face-to-face 
interface exist in the vancomycin-AcDA structure sug- 
gests that the interaction is not simply a fortuitous 
crystal contact and that the face-to-face configuration is 
thermodynamically favorable for the vancomycin- 
AcDA complex. Furthermore, it is clear that far more 
extensive face-to-face interactions are possible with 
longer natural ligands, and that this may increase the 
thermodynamic advantage of this configuration. 
The distance between the charged amino groups of van- 
cosamine in molecules VI and V3, and in V2 and V4, is 
13.6 A, which corresponds precisely to the minimum 
effective length for a linker segment joining these sites in 
covalently linked monomers [191, suggesting that the 
covalent linkages facilitate face-to-face rather than 
back-to-back interactions. This observation further sug- 
gests that the increased antimicrobial efficacy of cova- 
lently linked monomers is a result of the formation of a 
face-to-face complex rather than bringing a second 
monomer close to a second ligand. 
Materials and methods 
Materials 
Pharmaceutical grade vancomycin hydrochloride (Vancocin@, Eli Lilly) 
was used without further purification. /V-acetylated o-alanine was 
obtained from Sigma; other materials were of the highest purity available 
commercially. Crystals were grown by hanging drop vapor diffusion. 
Equal volumes of aqueous vancomycin hydrochloride (40 mg ml-‘) and 
reservoir buffer were mixed and equilibrated over reservoir buffer at 
20°C; the reservoir buffer was 2.1 M NaCl in 0.1 M /V-acetyl-o-alanine, 
pH 4.6. Prior to data collection, crystals were transferred to a solution of 
30% (v/v) glycerol in reservoir buffer, mounted in fiber loops, and flash- 
cooled by plunging into liquid N,. Crystals were maintained at -175% 
in a stream of N, gas during data collection. 
Data collection 
High-resolution data were collected at beamline Xl 2-B at NSLS, using a 
MAR 30 cm image plate detector. Because of overloading in the intense 
low resolution data, further data were taken from the same AcDA crystal 
using a MAR 30 cm detector mounted on a home source. These data 
were merged with the high resolution synchrotron data and used during 
refinement. Data were processed with DENZO and SCALEPACK; 
details are given in Table 1. 
Data processing 
Normalized structure factor magnitudes (IEls) were obtained using 
LEVY/EVAL [21]. A total of 150000 triples were generated from the 
largest 4000 E-magnitudes between resolution limits of 10.0 and 1 .O A. 
1000 trial structures were generated, each consisting of 100 randomly 
placed atoms. Each of the 1000 trial structures was then subjected to 
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Table 1 
Data collection and refinement statistics. 
Contents of unit cell 
Vancomycin 
Ligand 
Cl- ions 
Solvent Hz0 molecules 
Temperature 
Wavelength 
Spacegroup 
Unit cell: 
a 
b 
C 
a 
P 
Y 
Unit cell volume 
Maximum resolution 
No. of observations 
No. of independent reflections 
Completeness of data: 
8.0-l .o A 
l.l-l.OA 
R merge 
No. of restraints in refinement 
No. of least-squares parameters 
4 
4 
goodness of fit on F2 
minlmax peaks in difference Fourier 
4 x W-‘,,C’,N,O,, 
4 x CsHsNO, 
4 
96 
98 K 
0.978 All ,542 A 
Pl 
21.4(l) 
24.3(l) 
24.9(l) 
64.5(2)’ 
90.2(2Y 
81.0(2)’ 
11,544 As 
0.97 A 
91,923 
21,253 
83% 
68% 
0.046 
22,169 
4921 
0.123 
0.299 
1.04 
-1.09/l .05 e-/A3 
500 cycles of the cyclic Shake-and-Bake procedure [22,23], using a 
pre-release of SnB ~2.0 [24] (R. Miller and CM. Weeks, unpublished 
observations). Each Shake-and-Bake cycle consists of phase refine- 
ment, Fourier filtering, peak picking, and then a structure factor routine 
that is used to generate phases for the next cycle. Each instance of 
phase refinement consisted of making one complete pass through the 
4000 phases, where each phase was, in turn, perturbed by at most two 
90” shifts. For each phase, the original and perturbed phase values 
were evaluated in terms of the minimal function [22], which was used as 
a figure of merit. The phase value yielding the smallest value of this 
objective function was used to replace the current value of the phase 
under consideration. The number of peaks picked during the 500 cycles 
varied. During the first 100 cycles, only 20 peaks were selected in an 
attempt to anchor the heavier chlorine atoms. During cycles 101-200, 
50 peaks were picked; during cycles 201-300, 100 peaks were 
picked; and finally, during cycles 301-500, 150 peaks were picked. 
After processing several hundred trials, there was a small, but distinc- 
tive, break in the range of the final minimal function values. From past 
experience [22,23], we know that a bimodal histogram of final minimal 
function values is a strong indication of the presence of a solution. The 
single trial yielding the smallest minimal function value was then used as 
a starting point in an effort to obtain a more refined set of phases. We 
applied several rounds of Fourier recycling to this structure, using both 
SnB ~1.5 [25] and the prerelease of SnB ~2.0. During this recycling, 
we used 40000 triples generated from the top 4000 E-magnitudes. The 
parameter shift phase refinement procedure used phase shifts that were 
smaller than the 90” shifts used to obtain this starting set of phases. 
Further, during the Fourier recycling, we gradually extended the number 
of peaks from the 150 input peaks to 404 final peaks. 
Manual editing of the peaks produced by SnB yielded an initial model 
comprising 293 of the 404 vancomycin atoms in the unit cell. This 
structure was refined with SHELXL [26] using alternate rounds of atom 
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placement into difference maps and refinement. Minimization was per- 
formed against F2 using restraints on geometry and atomic displace- 
ment parameters; anisotropic displacement parameters were included 
at later stages in the refinement. Conjugate gradient refinement was 
used throughout, except for the final cycles, where blocked least- 
squares methods were used. 
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